UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Three-year overall survival for patients with advanced melanoma
treated with pembrolizumab in KEYNOTE-001.
Authors*: Caroline Robert, Antoni Ribas, Omid Hamid, Adil Daud, Jedd D. Wolchok, Anthony M. Joshua,
Wen-Jen Hwu, Jeffrey S. Weber, Tara C. Gangadhar, Richard Wayne Joseph, Roxana Stefania Dronca,
Amita Patnaik, Hassane M. Zarour, Richard Kefford, Peter Hersey, Xiaoyun Li, Scott J. Diede,
Scot Ebbinghaus, F. Stephen Hodi
Abstract #: 9503
Presentation Date/Time: Monday, June 6: 1:15 - 4:15 PM
Location: Arie Crown Theater
Session: Melanoma/Skin Cancers
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9503)
Daud Research Interests: Our group at UCSF is focused on developing new immunotherapy agents and
specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL-
12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this
work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination
treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development
of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at
UCSF, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can
predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets
of melanoma (and potentially other cancers).
http://cancer.ucsf.edu/people/profiles/daud_adil.3622
*UCSF authors in bold
85